Pharmacovigilance

The safety of our drugs is a topic of vital importance for all at Stendhal.

In reference to this, we have developed a program where we provide follow-up on all of our marketed products, not only for discovering new indications, but also for becoming aware of adverse events that may be possibly related.  Our program is based on the procedures established and opportunely communicated on suspected adverse events to the authorities in each of the countries where we are located.

We are committed to be fully informed on the possible safety problems of our patients and guarantee the authenticity and quality of the safety data gathered for a continuous review of the associated risks.
If you would like to contact someone at the Medical Direction or Department of Pharmacovigilance at Stendhal, click here.